 NEW YORK, March 24, 2021 PRNewswire -- BrainStorm Cell Therapeutics Inc. NASDAQ: BCLI, a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline data from the Companys Phase 2 trial evaluating three repeated administrations of NurOwn MSC-NTF cells, each given 2 months apart, as a treatment for progressive multiple sclerosis MS. The study achieved the primary endpoint of safety and improvements were observed in secondary endpoints spanning neurologic function, cognition, and biomarkers. 